288 related articles for article (PubMed ID: 8850108)
1. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
Le Pen C; Lévy E; Bonte J
Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
[TBL] [Abstract][Full Text] [Related]
4. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
5. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
8. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
Chin Med J (Engl); 1997 Nov; 110(11):834-8. PubMed ID: 9772413
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
[TBL] [Abstract][Full Text] [Related]
10. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
11. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
Ambrosioni E; Borghi C; Magnani B
N Engl J Med; 1995 Jan; 332(2):80-5. PubMed ID: 7990904
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
13. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
Pfeffer MA
Herz; 1993 Dec; 18 Suppl 1():430-5. PubMed ID: 8125423
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis and clinical practice.
Rector TS; Francis GS
J Am Coll Cardiol; 1995 Oct; 26(4):920-1. PubMed ID: 7560618
[No Abstract] [Full Text] [Related]
15. [Economical treatment of heart failure].
Sonntag F
Med Klin (Munich); 1996 Feb; 91(2):111. PubMed ID: 8850107
[No Abstract] [Full Text] [Related]
16. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
18. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
Mazzotta G; Vecchio C
G Ital Cardiol; 1994 Jan; 24(1):59-70. PubMed ID: 8200499
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.
Almbrand B; Johannesson M; Sjöstrand B; Malmberg K; Rydén L
Eur Heart J; 2000 May; 21(9):733-9. PubMed ID: 10739728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
